TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations

Leukemia and Lymphoma

Volumn 56, Issue 1, 2015, Pages 179-185

  Gebauer, Niklas ^a   Bernard, Veronica ^a   Gebauer, Wolfgang ^b   Thorns, Christoph ^a   Feller, Alfred C ^a   Merz, Hartmut ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b KLINIKUM OLDENBURG   (Germany)

Author keywords

BCL2; BCL6; cMYC; Double hit lymphomas; TP53

Indexed keywords

BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN; PROTEIN BCL 2;

ADULT; AGED; CELL TRANSFORMATION; FEMALE; GENE TRANSLOCATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MUTATION; ONCOGENE MYC; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; FEMALE; GENES, MYC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSLOCATION, GENETIC;

EID: 84922358243     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.907896     Document Type: Article

References (30)

1. Oft K, Wong G, Filippa DA, et al. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. Blood 1991;77:1508-1515.
2. Siebert R, Rosenwald A, Staudt LM, et al. Molecular features of B-cell lymphoma. Curr Opin Oncol 2001;13:316-24.
3. Taub R, Kirsch I, Morton C, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 1982;79:7837-7841.
4. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011;117:2319-2331.
5. Swerdlow SH, Campo E, Harris NL, et al. WHO classifcation of tumors of haematopoetic and lymphoid tissues. Lyon: IARC; 2008.
6. Perry AM, Crockett D, Dave BJ, et al. B-cell lymphoma, unclassifable, with features intermediate between difuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases. Br J Haematol 2013;162:40-49.
7. Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 2012;25:145-156.
8. Pillai RK, Sathanoori M, Van Oss SB, et al. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol 2013;37:323-332.
9. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and difuse large B-cell lymphoma. Am J Surg Pathol 2010;34:327-340.
10. Akyurek N, Uner A, Benekli M, et al. Prognostic signifcance of MYC, BCL2, and BCL6 rearrangements in patients with difuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 2012;118: 4173-4183.
11. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with difuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010; 28:3360-3365.
12. Niitsu N, Okamoto M, Miura I, et al. Clinical features and prognosis of de novo difuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009;23:777-783.
13. Hummel M, Bentink S, Berger H, et al. A biologic defnition of Burkitt's lymphoma from transcriptional and genomic profling. N Engl J Med 2006;354:2419-2430.
14. Seegmiller AC, Garcia R, Huang R, et al. Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas. Mod Pathol 2010;23:909-920.
15. Levine AJ, Oren M. Te frst 30 years of p53: growing ever more complex. Nat Rev Cancer 2009;9:749-758.
16. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009;137:413-431.
17. Xu-Monette ZY, Wu L, Visco C, et al. Mutational profle and prognostic signifcance of TP53 in difuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2012;120: 3986-3996.
18. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012;490:116-120.
19. Young KH, Leroy K, Moller MB, et al. Structural profles of TP53 gene mutations predict clinical outcome in difuse large B-cell lymphoma: an international collaborative study. Blood 2008; 112:3088-3098.
20. Cheung KJ, Horsman DE, Gascoyne RD. Te signifcance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol 2009;146:257-269.
21. Nunez G, Seto M, Seremetis S, et al. Growth-and tumor-promoting efects of deregulated BCL2 in human B-lymphoblastoid cells. Proc Natl Acad Sci USA 1989;86:4589-4593.
22. Iqbal J, Sanger WG, Horsman DE, et al. BCL2 translocation defnes a unique tumor subset within the germinal center B-cell-like difuse large B-cell lymphoma. Am J Pathol 2004;165:159-166.
23. Drakos E, Singh RR, Rassidakis GZ, et al. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). Leukemia 2011;25:856-867.
24. Lo Coco F, Gaidano G, Louie DC, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993;82:2289-2295.
25. Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82:1994-2004.
26. Symmans WF, Katz RL, Ordonez NG, et al. Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation. Acta Cytol 1995;39:673-682.
27. Pennanen H, Kuittinen O, Soini Y, et al. Prognostic signifcance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma. Eur J Haematol 2008;81:289-297.
28. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362:1417-1429.
29. Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011;29:2223-2229.
30. Rucker FG, Schlenk R F, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specifc copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012;119:2114-2121.